GHK — copper-binding regenerative tripeptide
3-residue peptide that chelates copper(II). Stimulates collagen synthesis and wound healing.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
FDA-tracked compound — synthesized for clinical/research use
Fork this card to add platform evidence →
FDA-tracked (reclassified Category 1, Feb 2026) — preclinical/clinical bioassay data exists
Fork this card to add platform evidence →
Snapshot
Class: Endogenous copper-binding tripeptide
Evidence tier: Vendor / sparse research entry
Status: Not FDA approved. No regulatory status data present.
Best-supported effect: available literature contains no evidence data for this card. GHK is described in available literature as a copper-binding regenerative tripeptide; no supporting evidence is attached.
Main caveat: No evidence data of any kind is present. All sections below reflect source absence, not absence of literature on GHK generally.
What this is
GHK (glycyl-L-histidyl-L-lysine) is an endogenous tripeptide first identified in human serum. It forms stable complexes with copper(II) and has been studied for potential wound-healing and skin-rejuvenation properties. No supporting evidence data is identified.
Claim check
No specific biological or therapeutic claims are supported by the available literature.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None identified | No human evidence identified |
| Animal | None identified | No animal evidence identified |
| In vitro | None identified | No assay evidence identified |
| Computational | None identified | No computational data identified |
| Mechanism | None identified | No mechanism data identified |
Open questions
available literature contains no content beyond the peptide name and descriptor. The following are implied gaps for future source enrichment:
- Sequence, formula, molecular weight, and structural data not present in source
- Evidence for any indication not present in source
- Regulatory status not present in source
- Safety profile not present in source
▸3-letter notation
▸citationbibtex
@peptide{pep00009,
sequence = {GHK},
target = {cosmeceutical},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}